Ambalal Sarabhai Enterprises is locked at upper circuit limit of Rs. 14.50, up by 0.65 points or 4.69% from its previous closing of Rs. 13.85 on the BSE.The scrip opened at Rs. 14.50 and has touched a high and low of Rs. 14.50 and Rs. 14.50 respectively. So far 18520 shares were traded on the counter.The BSE group `X` stock of face value Rs. 10 has touched a 52 week high of Rs. 21.60 on 10-Jan-2020 and a 52 week low of Rs. 9.05 on 16-Oct-2019.Last one week high and low of the scrip stood at Rs. 14.50 and Rs. 12.50 respectively. The current market cap of the company is Rs. 111.12 crore.The promoters holding in the company stood at 30.76%, while Institutions and Non-Institutions held 0.01% and 69.23% respectively.CoSara Diagnostics (CoSara), a Joint Venture (JV) company of Synbiotics, a wholly owned subsidiary of Ambalal Sarabhai Enterprises and CoDiagnostics Inc, USA, a Gujarat, India based molecular diagnostic Company, has received the Test License from Central Drugs Standard Control Organisation (CDSCO) to manufacture corona virus (COVID-19) diagnostic test kits.Ambalal Sarabhai Enterprises is engaged in manufacturing and marketing of pharmaceutical products, bulk drugs, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials.

Ambalal Sarabhai Enterprises is locked at upper circuit limit of Rs. 13.20, up by 0.60 points or 4.76% from its previous closing of Rs. 12.60 on the BSE.The scrip opened at Rs. 13.15 and has touched a high and low of Rs. 13.20 and Rs. 13.15 respectively. So far 15508 shares were traded on the counter.The BSE group `X` stock of face value Rs. 10 has touched a 52 week high of Rs. 21.60 on 10-Jan-2020 and a 52 week low of Rs. 9.04 on 26-Oct-2018.Last one week high and low of the scrip stood at Rs. 14.20 and Rs. 12.50 respectively. The current market cap of the company is Rs. 101.16 crore.The promoters holding in the company stood at 30.76% while Institutions and Non-Institutions held 0.01% and 69.23% respectively.CoSara Diagnostics (CoSara), a Joint Venture (JV) company of Synbiotics, a wholly owned subsidiary of Ambalal Sarabhai Enterprises and CoDiagnostics Inc, USA, a Gujarat, India based molecular diagnostic Company, has received the Test License from Central Drugs Standard Control Organisation (CDSCO) to manufacture corona virus (COVID-19) diagnostic test kits.Ambalal Sarabhai Enterprises is engaged in manufacturing and marketing of pharmaceutical products, bulk drugs, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials.

Ambalal Sarabhai Enterprises is currently trading at upper circuit of Rs. 12.43, up by 2.07 points or 19.98% from its previous closing of Rs. 10.36 on the BSE.The scrip opened at Rs. 11.85 and has touched a high and low of Rs. 12.43 and Rs. 11.25 respectively. So far 75069 shares were traded on the counter.The BSE group `X` stock of face value Rs. 10 has touched a 52 week high of Rs. 16.45 on 10-Apr-2019 and a 52 week low of Rs. 9.05 on 16-Oct-2019.Last one week high and low of the scrip stood at Rs. 12.45 and Rs. 10.01 respectively. The current market cap of the company is Rs. 95.26 crore.The promoters holding in the company stood at 30.76%, while Institutions and Non-Institutions held 0.01% and 69.24% respectively.CoSara Diagnostics, a joint venture company of Co-Diagnostics Inc., USA and a Synbiotics, a wholly owned subsidiary of Ambalal Sarabhai Enterprises, has obtained regulatory clearance for five tests to be manufactured and sold as in vitro diagnostics (IVDs) from their facility in Ranoli India.The test for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus (HPV) meet the requirements of the Central Drug Standard Control Organization (CDSCO) Medical Device Rules (MDR), 2017.Regulatory clearance allows CoSara for the first time to manufacture and sell the test for the detection of the respective pathogens and microorganisms.Ambalal Sarabhai Enterprises is engaged in manufacturing and marketing of pharmaceutical products, bulk drugs, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials.

A slight decline in the revenue of Rs. 0.00 millions was seen for the September 2019 quarter as against Rs. 0.00 millions during year-ago period.The Total Profit for the quarter ended September 2019 of Rs. 4.44 millions grew from Rs.-19.29 millions Operating profit Margin for the quarter ended September 2019 improved to 1.83% as compared to -10.28% of corresponding quarter ended September 2018 (Rs. in Million) Quarter ended Year to Date Year ended 201909 201809 % Var 201909 201809 % Var 201903 201803 % Var Sales 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.24 0.00 Other Income 21.78 11.33 92.23 50.79 18.73 171.17 64.63 244.95 -73.62 PBIDT 1.83 -10.28 -117.80 8.51 -27.94 -130.46 -24.04 36.48 -165.90 Interest 0.00 1.46 -100.00 0.89 4.07 -78.13 6.20 10.45 -40.67 PBDT 1.83 -11.74 -115.59 7.62 -32.01 -123.81 -30.24 26.03 -216.17 Depreciation 0.00 1.12 0.00 0.96 2.08 -53.85 4.00 4.16 -3.85 PBT 1.83 -12.86 -114.23 6.66 -34.09 -119.54 -34.24 21.87 -256.56 TAX -2.61 6.42 -140.65 -4.60 6.70 -168.66 4.55 36.25 -87.45 Deferred Tax 0.00 6.42 0.00 -1.99 6.70 -129.70 4.55 3.01 51.16 PAT 4.44 -19.29 -123.02 11.27 -40.80 -127.62 -38.80 -14.38 169.82 Equity 0.00 766.33 0.00 766.33 766.33 0.00 766.33 766.33 0.00 PBIDTM(%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 394.81 -100.00

A minor change in the total revenue was seen in the December 2018 quarter. The total revenue for the quarter stood at Rs. 0.00 millions against Rs. 1.11 millions during year ago period.The Net Loss for the quarter ended December 2018 is Rs. -6.68 millions as compared to Net Profit of Rs. 14.39 millions of corresponding quarter ended December 2017Operating profit Margin for the quarter ended December 2018 slipped to -5.86% as compared to 12.48% of corresponding quarter ended December 2017 (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201803 201703 % Var Sales 0.00 1.11 0.00 0.00 5.86 0.00 9.24 15.12 -38.89 Other Income 13.90 33.39 -58.37 32.63 50.32 -35.16 244.95 71.94 240.49 PBIDT -5.86 12.48 -146.96 -33.80 -17.76 90.32 36.49 -135.97 -126.84 Interest 3.46 1.98 74.75 7.53 13.10 -42.52 10.45 26.16 -60.05 PBDT -9.32 10.50 -188.76 -41.33 -30.86 33.93 26.03 -162.13 -116.06 Depreciation 0.95 0.52 82.69 3.03 2.95 2.71 4.16 24.50 -83.02 PBT -10.27 9.98 -202.91 -44.36 -33.81 31.20 21.87 -186.63 -111.72 TAX -3.59 -4.41 -18.59 3.11 -13.22 -123.52 36.25 19.03 90.49 Deferred Tax -3.59 -4.41 -18.59 3.11 -13.22 -123.52 3.01 -4.62 -165.15 PAT -6.68 14.39 -146.42 -47.48 -20.59 130.60 -14.38 -205.65 -93.01 Equity 766.33 766.33 0.00 766.33 766.33 0.00 766.33 766.33 0.00 PBIDTM(%) 0.00 1124.32 -100.00 0.00 -303.07 0.00 394.81 -899.27 -143.90

The sales is pegged at Rs. 1.11 millions for the December 2017 quarter. The mentioned figure indicates a decline of about -56.47% as against Rs. 2.55 millions during the year-ago period.The Total Profit for the quarter ended December 2017 of Rs. 14.39 millions grew from Rs.-19.65 millions Operating profit Margin for the quarter ended December 2017 improved to 12.48% as compared to -18.42% of corresponding quarter ended December 2016 (Rs. in Million) Quarter ended Year to Date Year ended 201712 201612 % Var 201712 201612 % Var 201703 201603 % Var Sales 1.11 2.55 -56.47 5.86 9.86 -40.57 15.12 69.86 -78.36 Other Income 33.39 9.32 258.26 50.32 46.41 8.42 70.26 959.42 -92.68 PBIDT 12.48 -18.42 -167.75 -17.76 -62.03 -71.37 -141.13 743.00 -118.99 Interest 1.98 2.39 -17.15 13.10 15.12 -13.36 26.16 19.95 31.13 PBDT 10.50 -20.81 -150.46 -30.86 -77.15 -60.00 -167.29 723.05 -123.14 Depreciation 0.52 7.06 -92.63 2.95 21.27 -86.13 24.50 146.21 -83.24 PBT 9.98 -27.87 -135.81 -33.81 -98.42 -65.65 -191.80 576.84 -133.25 TAX -4.41 -8.22 -46.35 -13.22 -14.81 -10.74 23.65 120.00 -80.29 Deferred Tax -4.41 -3.29 34.04 -13.22 -9.88 33.81 0.00 0.00 0.00 PAT 14.39 -19.65 -173.23 -20.59 -83.62 -75.38 -215.45 456.84 -147.16 Equity 766.33 766.33 0.00 766.33 766.33 0.00 766.33 766.33 0.00 PBIDTM(%) 1124.32 -722.35 -255.65 -303.07 -629.11 -51.83 -933.47 1063.56 -187.77

Ambalal Sarabhai Enterprises has informed that the meeting of the Board of Directors of the Company will be held on February 09, 2017, to consider and take on record the unaudited financial results of the Company together with Limited Review Report for the quarter ended December 31, 2016.The above information is a part of company’s filings submitted to BSE.

Ambalal Sarabhai Enterprises has informed that the address of the Company’s registered office has been changed from Sarabhai Campus, Gorwa Road, Vadodara -390023 to Shanti sadan, Mirzapur Road, Ahmedabad - 380001 with effect from November 09, 2015.The above information is a part of company’s filings submitted to BSE.

The Exchange has sought clarification from Ambalal Sarabhai Enterprises with reference to increase in price on April 07, 2015. The reply is awaited.The above information is a part of company’s filings submitted to BSE.

Ambalal Sarabhai Enterprises has informed that the 35th Annual General Meeting which was adjourned on September 30, 2013 will now be held on November 13, 2013 at 10.30 a.m. at Prof. C. C. Mehta Auditorium, The Maharaja Sayajirao University, Vadodara, to transact all the business as specified in Notice dated August 23, 2013. The above information is a part of company’s filings submitted to BSE.

Ambalal Sarabhai Enterprises has informed about the financial results & a copy of the limited review report for the period ended September 30, 2012.The above information is a part of company's filings submitted to BSE.